 | • レポートコード：GIR201107868 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、再発急性骨髄性白血病（AML）治療薬の世界市場を調査対象にし、再発急性骨髄性白血病（AML）治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（aNKプログラム、AT-9283、BI-836858、ビニメチニブ、BL-8040、その他）、用途別分析（クリニック、病院、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：4SC AG、Astellas Pharma Inc.、Agios Pharmaceuticals, Inc.、AbbVie Inc.、Array BioPharma Inc.、Actinium Pharmaceuticals, Inc.、AstraZeneca Plc、Arog Pharmaceuticals, Inc.、Amgen Inc.、Astex Pharmaceuticals, Inc.、Bristol-Myers Squibb Company、Cornerstone Pharmaceuticals, Inc.、AVEO Pharmaceuticals, Inc.、Calithera Biosciences, Inc.、Boston Biomedical, Inc.、BioLineRx, Ltd.、CTI BioPharma Corp.、Celgene Corporation、Boehringer Ingelheim GmbH ・メーカー別販売量、売上、市場シェア ・再発急性骨髄性白血病（AML）治療薬の地域別市場分析 ・再発急性骨髄性白血病（AML）治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・再発急性骨髄性白血病（AML）治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・再発急性骨髄性白血病（AML）治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・再発急性骨髄性白血病（AML）治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・再発急性骨髄性白血病（AML）治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・再発急性骨髄性白血病（AML）治療薬の種類別市場規模2015-2020：aNKプログラム、AT-9283、BI-836858、ビニメチニブ、BL-8040、その他 ・再発急性骨髄性白血病（AML）治療薬の用途別市場規模2015-2020：クリニック、病院、その他 ・再発急性骨髄性白血病（AML）治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Relapsed Acute Myeloid Leukemia Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Relapsed Acute Myeloid Leukemia Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Relapsed Acute Myeloid Leukemia Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Relapsed Acute Myeloid Leukemia Drug market has been segmented into
aNK Program
AT-9283
BI-836858
binimetinib
BL-8040
Others
By Application, Relapsed Acute Myeloid Leukemia Drug has been segmented into:
Clinic
Hospital
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Relapsed Acute Myeloid Leukemia Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Relapsed Acute Myeloid Leukemia Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Relapsed Acute Myeloid Leukemia Drug market.
The report offers in-depth assessment of the growth and other aspects of the Relapsed Acute Myeloid Leukemia Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Relapsed Acute Myeloid Leukemia Drug Market Share Analysis
Relapsed Acute Myeloid Leukemia Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Relapsed Acute Myeloid Leukemia Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Relapsed Acute Myeloid Leukemia Drug sales, revenue and market share for each player covered in this report.
The major players covered in Relapsed Acute Myeloid Leukemia Drug are:
4SC AG
Astellas Pharma Inc.
Agios Pharmaceuticals, Inc.
AbbVie Inc.
Array BioPharma Inc.
Actinium Pharmaceuticals, Inc.
AstraZeneca Plc
Arog Pharmaceuticals, Inc.
Amgen Inc.
Astex Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Cornerstone Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Calithera Biosciences, Inc.
Boston Biomedical, Inc.
BioLineRx, Ltd.
CTI BioPharma Corp.
Celgene Corporation
Boehringer Ingelheim GmbH
Among other players domestic and global, Relapsed Acute Myeloid Leukemia Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Relapsed Acute Myeloid Leukemia Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Relapsed Acute Myeloid Leukemia Drug, with price, sales, revenue and global market share of Relapsed Acute Myeloid Leukemia Drug in 2018 and 2019.
Chapter 3, the Relapsed Acute Myeloid Leukemia Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Relapsed Acute Myeloid Leukemia Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Relapsed Acute Myeloid Leukemia Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Relapsed Acute Myeloid Leukemia Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Relapsed Acute Myeloid Leukemia Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Overview of Global Relapsed Acute Myeloid Leukemia Drug Market
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 4SC AG
2.1.1 4SC AG Details
2.1.2 4SC AG Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 4SC AG SWOT Analysis
2.1.4 4SC AG Product and Services
2.1.5 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Astellas Pharma Inc.
2.2.1 Astellas Pharma Inc. Details
2.2.2 Astellas Pharma Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Astellas Pharma Inc. SWOT Analysis
2.2.4 Astellas Pharma Inc. Product and Services
2.2.5 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Agios Pharmaceuticals, Inc.
2.3.1 Agios Pharmaceuticals, Inc. Details
2.3.2 Agios Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Agios Pharmaceuticals, Inc. SWOT Analysis
2.3.4 Agios Pharmaceuticals, Inc. Product and Services
2.3.5 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 AbbVie Inc.
2.4.1 AbbVie Inc. Details
2.4.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AbbVie Inc. SWOT Analysis
2.4.4 AbbVie Inc. Product and Services
2.4.5 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Array BioPharma Inc.
2.5.1 Array BioPharma Inc. Details
2.5.2 Array BioPharma Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Array BioPharma Inc. SWOT Analysis
2.5.4 Array BioPharma Inc. Product and Services
2.5.5 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Actinium Pharmaceuticals, Inc.
2.6.1 Actinium Pharmaceuticals, Inc. Details
2.6.2 Actinium Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Actinium Pharmaceuticals, Inc. SWOT Analysis
2.6.4 Actinium Pharmaceuticals, Inc. Product and Services
2.6.5 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 AstraZeneca Plc
2.7.1 AstraZeneca Plc Details
2.7.2 AstraZeneca Plc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 AstraZeneca Plc SWOT Analysis
2.7.4 AstraZeneca Plc Product and Services
2.7.5 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Arog Pharmaceuticals, Inc.
2.8.1 Arog Pharmaceuticals, Inc. Details
2.8.2 Arog Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Arog Pharmaceuticals, Inc. SWOT Analysis
2.8.4 Arog Pharmaceuticals, Inc. Product and Services
2.8.5 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Amgen Inc.
2.9.1 Amgen Inc. Details
2.9.2 Amgen Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Amgen Inc. SWOT Analysis
2.9.4 Amgen Inc. Product and Services
2.9.5 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Astex Pharmaceuticals, Inc.
2.10.1 Astex Pharmaceuticals, Inc. Details
2.10.2 Astex Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Astex Pharmaceuticals, Inc. SWOT Analysis
2.10.4 Astex Pharmaceuticals, Inc. Product and Services
2.10.5 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Bristol-Myers Squibb Company
2.11.1 Bristol-Myers Squibb Company Details
2.11.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Bristol-Myers Squibb Company SWOT Analysis
2.11.4 Bristol-Myers Squibb Company Product and Services
2.11.5 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Cornerstone Pharmaceuticals, Inc.
2.12.1 Cornerstone Pharmaceuticals, Inc. Details
2.12.2 Cornerstone Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Cornerstone Pharmaceuticals, Inc. SWOT Analysis
2.12.4 Cornerstone Pharmaceuticals, Inc. Product and Services
2.12.5 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 AVEO Pharmaceuticals, Inc.
2.13.1 AVEO Pharmaceuticals, Inc. Details
2.13.2 AVEO Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 AVEO Pharmaceuticals, Inc. SWOT Analysis
2.13.4 AVEO Pharmaceuticals, Inc. Product and Services
2.13.5 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Calithera Biosciences, Inc.
2.14.1 Calithera Biosciences, Inc. Details
2.14.2 Calithera Biosciences, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Calithera Biosciences, Inc. SWOT Analysis
2.14.4 Calithera Biosciences, Inc. Product and Services
2.14.5 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Boston Biomedical, Inc.
2.15.1 Boston Biomedical, Inc. Details
2.15.2 Boston Biomedical, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Boston Biomedical, Inc. SWOT Analysis
2.15.4 Boston Biomedical, Inc. Product and Services
2.15.5 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 BioLineRx, Ltd.
2.16.1 BioLineRx, Ltd. Details
2.16.2 BioLineRx, Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 BioLineRx, Ltd. SWOT Analysis
2.16.4 BioLineRx, Ltd. Product and Services
2.16.5 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 CTI BioPharma Corp.
2.17.1 CTI BioPharma Corp. Details
2.17.2 CTI BioPharma Corp. Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 CTI BioPharma Corp. SWOT Analysis
2.17.4 CTI BioPharma Corp. Product and Services
2.17.5 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 Celgene Corporation
2.18.1 Celgene Corporation Details
2.18.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Celgene Corporation SWOT Analysis
2.18.4 Celgene Corporation Product and Services
2.18.5 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 Boehringer Ingelheim GmbH
2.19.1 Boehringer Ingelheim GmbH Details
2.19.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Boehringer Ingelheim GmbH SWOT Analysis
2.19.4 Boehringer Ingelheim GmbH Product and Services
2.19.5 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Relapsed Acute Myeloid Leukemia Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Relapsed Acute Myeloid Leukemia Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
4.3 Europe Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
4.5 South America Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Country
5.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
5.3 Canada Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
6.3 UK Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
6.4 France Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
6.5 Russia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
6.6 Italy Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7.3 Japan Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7.4 Korea Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7.5 India Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
7.7 Australia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Country
8.1.1 South America Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Relapsed Acute Myeloid Leukemia Drug Sales and Market Share by Type (2015-2020)
10.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2015-2020)
11 Global Relapsed Acute Myeloid Leukemia Drug Market Segment by Application
11.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2015-2020)
11.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2015-2020)
11.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Relapsed Acute Myeloid Leukemia Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025)
12.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025)
12.2.4 South America Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025)
12.3 Relapsed Acute Myeloid Leukemia Drug Market Forecast by Type (2021-2025)
12.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Type (2021-2025)
12.4 Relapsed Acute Myeloid Leukemia Drug Market Forecast by Application (2021-2025)
12.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Relapsed Acute Myeloid Leukemia Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Relapsed Acute Myeloid Leukemia Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. 4SC AG Basic Information, Manufacturing Base and Competitors
Table 8. 4SC AG Relapsed Acute Myeloid Leukemia Drug Major Business
Table 9. 4SC AG Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 10. 4SC AG SWOT Analysis
Table 11. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 12. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 15. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 16. Astellas Pharma Inc. SWOT Analysis
Table 17. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 18. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Agios Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 21. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 22. Agios Pharmaceuticals, Inc. SWOT Analysis
Table 23. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 24. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 26. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 27. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 28. AbbVie Inc. SWOT Analysis
Table 29. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 30. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Array BioPharma Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 33. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 34. Array BioPharma Inc. SWOT Analysis
Table 35. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 36. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Actinium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 38. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 39. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 40. Actinium Pharmaceuticals, Inc. SWOT Analysis
Table 41. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 42. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. AstraZeneca Plc Basic Information, Manufacturing Base and Competitors
Table 44. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Major Business
Table 45. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 46. AstraZeneca Plc SWOT Analysis
Table 47. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 48. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Arog Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 50. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 51. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 52. Arog Pharmaceuticals, Inc. SWOT Analysis
Table 53. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 54. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 57. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 58. Amgen Inc. SWOT Analysis
Table 59. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 60. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Astex Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 62. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 63. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 64. Astex Pharmaceuticals, Inc. SWOT Analysis
Table 65. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 66. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 68. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Major Business
Table 69. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 70. Bristol-Myers Squibb Company SWOT Analysis
Table 71. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 72. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Cornerstone Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 75. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 76. Cornerstone Pharmaceuticals, Inc. SWOT Analysis
Table 77. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 78. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. AVEO Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 80. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 81. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 82. AVEO Pharmaceuticals, Inc. SWOT Analysis
Table 83. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 84. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Calithera Biosciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 86. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 87. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 88. Calithera Biosciences, Inc. SWOT Analysis
Table 89. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 90. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Boston Biomedical, Inc. Basic Information, Manufacturing Base and Competitors
Table 92. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 93. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 94. Boston Biomedical, Inc. SWOT Analysis
Table 95. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 96. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. BioLineRx, Ltd. Basic Information, Manufacturing Base and Competitors
Table 98. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 99. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 100. BioLineRx, Ltd. SWOT Analysis
Table 101. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 102. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. CTI BioPharma Corp. Basic Information, Manufacturing Base and Competitors
Table 104. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Major Business
Table 105. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 106. CTI BioPharma Corp. SWOT Analysis
Table 107. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 108. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Type and Application
Table 110. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Major Business
Table 111. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 112. Celgene Corporation SWOT Analysis
Table 113. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 114. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 115. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 116. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Major Business
Table 117. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Total Revenue (USD Million) (2018-2019)
Table 118. Boehringer Ingelheim GmbH SWOT Analysis
Table 119. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 120. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 121. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 122. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 123. Global Relapsed Acute Myeloid Leukemia Drug Sales by Regions (2015-2020) (K Pcs)
Table 124. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Regions (2015-2020)
Table 125. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Regions (2015-2020) (USD Million)
Table 126. North America Relapsed Acute Myeloid Leukemia Drug Sales by Countries (2015-2020) (K Pcs)
Table 127. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries (2015-2020)
Table 128. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Countries (2015-2020) (USD Million)
Table 129. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020)
Table 130. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Countries (2015-2020) (K Pcs)
Table 131. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries (2015-2020)
Table 132. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Countries (2015-2020) (USD Million)
Table 133. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Regions (2015-2020) (K Pcs)
Table 134. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Regions (2015-2020)
Table 135. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Regions (2015-2020) (USD Million)
Table 136. South America Relapsed Acute Myeloid Leukemia Drug Sales by Countries (2015-2020) (K Pcs)
Table 137. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries (2015-2020)
Table 138. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Countries (2015-2020) (USD Million)
Table 139. South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020)
Table 140. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Countries (2015-2020) (K Pcs)
Table 141. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries (2015-2020)
Table 142. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Countries (2015-2020) (USD Million)
Table 143. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020)
Table 144. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 145. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2015-2020)
Table 146. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2015-2020) (USD Million)
Table 147. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2015-2020)
Table 148. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 149. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2015-2020)
Table 150. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 151. Global Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Regions (2021-2025)
Table 152. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 153. Global Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Type (2021-2025)
Table 154. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2021-2025)
Table 155. Global Relapsed Acute Myeloid Leukemia Drug Market Share Forecast by Application (2021-2025)
Table 156. Direct Channel Pros & Cons
Table 157. Indirect Channel Pros & Cons
Table 158. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Picture
Figure 2. Global Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Type in 2019
Figure 3. aNK Program Picture
Figure 4. AT-9283 Picture
Figure 5. BI-836858 Picture
Figure 6. binimetinib Picture
Figure 7. BL-8040 Picture
Figure 8. Others Picture
Figure 9. Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application in 2018
Figure 10. Clinic Picture
Figure 11. Hospital Picture
Figure 12. Others Picture
Figure 13. Global Relapsed Acute Myeloid Leukemia Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturer in 2019
Figure 34. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Relapsed Acute Myeloid Leukemia Drug Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Relapsed Acute Myeloid Leukemia Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Regions (2015-2020)
Figure 41. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Regions in 2018
Figure 42. North America Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
Figure 43. Europe Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
Figure 45. South America Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020)
Figure 47. North America Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries (2015-2020)
Figure 49. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries in 2018
Figure 50. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries in 2018
Figure 52. United States Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries in 2019
Figure 58. Germany Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Regions 2019
Figure 66. China Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries in 2019
Figure 73. South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries in 2019
Figure 74. Brazil Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
血液がん治療の世界市場 2020年 Market Overview The global Blood Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Blood Cancer Therap…- 急性片頭痛治療の世界市場 2020年 Market Overview The global Acute Migraine Treatments market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Acute Migraine Trea…
- 有毛細胞白血病治療薬の世界市場 2020年 Market Overview The global Hairy Cell Leukemia Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.6% in the forecast period of 2020 to 2025 and will expected to reach USD 105.3 million by 2025, from USD 88 million in 2019. The Hairy Ce…
- 急性片頭痛薬の世界市場 2020年 Market Overview The global Acute Migraine Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Acute Migraine Drugs mar…
- B細胞慢性リンパ性白血病治療の世界市場 2020年 Market Overview The global B-Cell Chronic Lymphocytic Leukemia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The…